drugset / Trial / NCT06905847
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation
RandomizedSequentialQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy of HSK39004 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease（COPD）.
Timeline
- Start
- 2024-09-02
- Primary completion
- 2025-01-13
- Completion
- 2025-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK39004 | Unknown | 1.5 mg | Inhaled |
| Subject | HSK39004 | Unknown | 6 mg | Inhaled |
| Subject | HSK39004 | Unknown | 12 mg | Inhaled |
Indications
No indication recorded.